FRMD3

Across TCGA pan-cancer cohorts, FRMD3 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of FRMD3’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where FRMD3 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types FRMD3 is over-expressed in tumor, although a few such as CCRCC and HNSC show the opposite, repressed pattern.

CCRCC, HNSC, and LUAD are the cancer types where FRMD3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FRMD3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	II,III,IV	−0.863	<.001	11	view →
HNSC	All	All	−1.929	<.001	8	view →
LUAD	Male	III,IV	−1.762	<.001	8	view →
LSCC	Male	All	−1.477	<.001	8	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

FRMD3–CCRCC

Open the CCRCC breakdown →